Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis

Naini, Afsoon Emami; Asiabi, Reza Ebrahimi Kord; Keivandarian, Noushin; Moeinzadeh, Firouzeh

Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis

Authors

Department of Internal Medicine, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: End stage renal disease (ESRD) is a state of micro inflammation that attenuates patient's life span and quality of life. Inflammatory markers like interlukin 6 (IL-6) and C- reactive protein (CRP) can predict inflammatory state in ESRD patients. Dietary limitations are risk factors for omega-3 deficiency in these patients. Omega-3 supplementation is an attractive material that proposed in inflammation modulation. The aim of this study is evaluation of effect of omega-3 supplementation on IL-6 and CRP level in chronic ambulatory peritoneal dialysis (CAPD) patients.
Materials and Methods: This randomized controlled double-blind clinical trial is performed in 40 CAPD patients in two academic hospitals in Isfahan, Iran. One group received 1000 mg omega-3 capsule (each capsule contains 180 mg Eicosapentanoic and 120 mg Dosahexanoic acid) three times a day orally for 8 weeks (n = 20) and the other matched group by placebo (n = 20). Serum level of IL-6 and quantitative CRP (Q-CRP) were measured in beginning and the end of the study. Finally all data were analyzed by SPSS version 18.
Results: Mean age of patients was 53 years old in omega-3 group patients and 54 years old in placebo group. There were not any differences in CRP and IL-6 level in the beginning and the end of study between two groups (P: 0.81 and 0.10 for CRP and 0.26 and 0.23 for IL-6, respectively).
Conclusion: Omega-3 supplementation did not effect on inflammatory markers (Q-CRP and IL-6) in CAPD patients after 8 weeks.

Keywords

References

1.	Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004;38:405-16.
2.	Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 2005;293:1737-45.
3.	Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int 2005;67:1216-33.
4.	Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol 2013;9:255-65.
5.	Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 2003;18:1272-80.
6.	Axelsson J, Qureshi AR, Suliman ME, Honda H, Pecoits-Filho R, Heimbu¨rger O, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004;80:1222-9.
7.	Tavafi M. Diabetic nephropathy and antioxidants. J Nephropathol 2013;2:20-7.
8.	Schwedler S, Filep J, Galle J, Wanner C, Potempa LA. C-Reactive Protein: A family of proteins to regulate cardiovascular function. Am J Kidney Dis 2006;47:212-22.
9.	Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65:2371-9.
10.	Nasri H. Serum C reactive protein (CRP) in association with various nutritional parameters in maintenance hemodialysis patients. Bratisl Lek Listy 2005;106:390-5.
11.	Jones S, Horiuchi S, Topley N, Yamamoto N, Fuller G. The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. FASEB J 2001;15:43-58.
12.	Memoli B, Romano G, D'Arcangelo R, Del Prete M, Esposito P, Procino A, et al. The Role of Interleukin-6 and of Its Soluble Receptors in the Biocompatibility of Dialysis Treatment. Semin Nephrol 2004;24:492-4.
13.	Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
14.	Tayyebi-Khosroshahi H, Houshyar J, Tabrizi A, Vatankhah AM, Razzagi Zonouz N, Dehghan-Hesari R. Effect of Omega-3 Fatty Acid on Oxidative Stress in Patients on Hemodialysis. Iran J Kidney Dis 2010;4:322-6.
15.	Pekovic PG, Milutinovic RZ, Gluvic Z, Lackovic M, Medic DR, Glibetic M. Inflammation, nutritional status PUFA profile and outcome in hemodialysis patients. Arch Biol Sci 2012;64:1173-80.
16.	Filiopoulos V, Hadjiyannakos D, Takouli L, Metaxaki P, Sideris P, Vlassopoulos D. Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Int J Artif Organs 2009;32:872-82.
17.	Taheri S, Keyvandarian N, Moeinzadeh F, Mortazavi M, Emami Naini AE. The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients. Adv Biomed Res 2014;3:143. [PUBMED]
18.	Friedman A, Moe S. Review of the Effects of Omega-3 Supplementation in Dialysis Patients. Clin J Am Soc Nephrol 2006;1:182-92.
19.	Stenvinkel P. Inflammatory and atherosclerosis interactions in the depleted uremic patients. Blood Purif 2001;19:53-61.
20.	Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses 2004;62:499-506.
21.	Stenvinkel P. Inflammation in end-stage renal disease: The hidden enemy. Nephrol 2006;11:36-41.
22.	Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi SH, McGee JC, Minagar A. Effect of agnesium Supplementation on Carotid Intima-Media Thickness and Flow-Mediated Dilatation among Hemodialysis Patients: A Double-Blind, Randomized, Placebo-Controlled Trial. Eur Neurol 2013;69:309-16.
23.	Guo CH, Wang CL. Effects of Zinc Supplementation on Plasma Copper/Zinc Ratios, Oxidative Stress, and Immunological Status in Hemodialysis Patients. Int J Med Sci 2013;10:79-89.
24.	Sahni N, Gupta KL. Dietary antioxidants and oxidative stress in predialysis chronic kidney disease patients. J Nephropathology 2012;1:134-42.
25.	Hussein N, Ah-Sing E, Wilkinson P, Leach C, Griffin BA, Millward DJ. Long-chain conversion of [13C] linoleic acid and alpha-linolenic acid in response to marked changes in their dietary intake in men. J Lipid Re 2005;46:269-80.
26.	De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994;14:1829-36.
27.	Calder PC. Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease' PUFA, inflammatory processes and rheumatoid arthritis. Proceedings of the Nutrition Society 2008;67:409-18.
28.	Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric- coated fish oil preparation on relapses in Crohn s disease. N Engl J Med 1996;334:1557-60.
29.	Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994;331:1194-9.
30.	Fetterman JW Jr, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 2009;66:1169-79.
31.	Madsen T, Schmidt EB, Christensen JB. The effect of n-3 fatty acids on C- reactive protein levels in patients with chronic renal failure. J Ren Nutr 2007;17:258-63.
32.	Tayyebi-Khosroshahi H, Houshyar J, Dehghan-Hesari R, Alikhah H, Vatankhah A, Safaeian AR, et al. Effect of treatment with Omega-3 Fatty Acid on C reactive protein and tumor necrosis factor-alfa in hemodialysis patients. Saudi J Kidney Dis Transpl 2012;23:500-6. [PUBMED]
33.	Şahinarslan A, Güz G, Mutluay R, Okyay K, Demirtaş C, Paşaoğlu H, et al. The impact of dialysis type on biomarkers for cardiovascular diseases. Arch Turk Soc Cardiol 2011;39:456-62.

Advanced Biomedical Research